Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Rydberg-atom RF Sensors for Direction Finding and Geolocation (RADARS)

    SBC: Coldquanta, Inc.            Topic: AF17AT028

    ColdQuanta, in partnership with Dr. Zoya Popovic at the University of Colorado at Boulder, proposes to develop a three-dimensional quantum-enhanced radio-frequency (RF) signal sensor and direction finder. Our approach combines Rydberg-atom-based RF electrometry and discrete lens arrays (DLAs) of planar antennas. The DLA will serve as a Fourier optic for an incident wave, and a Rydberg-atom RF elec ...

    STTR Phase II 2019 Department of DefenseAir Force
  2. Resilient Directional Mesh Enhanced Tactical Airborne Networks

    SBC: First RF Corporation            Topic: AF17BT003

    FIRST RF will lead the Phase II effort and will leverage the system architecture of the MAINLINE system and integrate multifunctional SiGe integrated circuits (ICs) developed by The University of California San Diego under the supervision of Prof. Gabriel Rebeiz. The SiGe devices developed during the Phase II effort will significantly reduce the power requirements of the MAINLINE system allowing f ...

    STTR Phase II 2019 Department of DefenseAir Force
  3. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    TypeDiabetesT Daffects an ever growing populationWhile this disease typically has been associated with juvenilesthe disease in adult populations is rapidly increasingThe defining clinical component is insulin losswhich occurs because of sustained inflammation in the isletsAt present there is no means to prevent or reverse insulin lossA major inflammatory pathway in T D that contributes to insulin ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: Cetya Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY Thehemoglobinopathies are prevalent genetic blood diseases with few treatment optionsIt is estimate thatof the worldandapos s population carries an abnormal hemoglobin gene withinfants born annually with a severe life threatening hemoglobinopathyDrug mediated induction of normalbut developmentally silencedfetal hemoglobinHbFexpression reduces anemia and ameliorates clinical severit ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government